Inovio Pharmaceuticals Inc vs ABRDN Physical Gold Shares ETF — how do they compare? Inovio Pharmaceuticals Inc trades at $0.8 (market cap $78.55M), while ABRDN Physical Gold Shares ETF trades at $41.87. The key difference: ABRDN Physical Gold Shares ETF is trading nearer its 52-week high, Inovio Pharmaceuticals Inc nearer its low. Which is the better fit depends on your goals.
| INO | SGOL | |
|---|---|---|
Market Cap | $78.55M | — |
Sector | Health | Commodities - Metals/Agriculture |
52-Week High | $2.87 | $51.41 |
52-Week Low | $0.66 | $31.61 |
Enterprise Value | $49.56M | — |
Signals from Pluang's Aura AI — not financial advice
INO trades at $0.772, up 4.83% in the last 24 hours, but technical indicators signal a bearish trend. The company shows minimal revenue of $65,340 in 2025 with a net loss of $84.95 million, though it has beaten EPS estimates in recent quarters. Key developments include an upcoming Q2 2026 earnings report on August 12, 2026, and a pending FDA decision on INO-3107 by October 30, 2026.
The outlook hinges on FDA approval of INO-3107, with a consensus price target of $3.25 implying significant upside. However, high cash burn, negative margins, and legal scrutiny pose substantial risks. Investors should weigh the binary event against persistent financial challenges.
SGOL trades at $42.03, up 0.55% today, with a bullish technical signal from moving averages but overbought RSI readings. Recent gold price strength is driven by cooling U.S. inflation data and central bank demand, as spot gold surpassed $4,430/oz following July CPI data (Kitco, 2026-08-12). The stock lacks disclosed financial ratios, limiting fundamental analysis.
Outlook remains positive near-term due to gold's momentum, but high RSI suggests potential pullback risks. Investment appeal hinges on gold's macro trends; key risks include Fed policy shifts and dollar volatility. Analyst sentiment is mixed with technical indicators signaling caution despite bullish price action.
Trailing returns across standard periods
Latest headlines on both assets
Inovio Pharmaceuticals Inc is a United States based biotechnology company that develops active DNA-based immunotherapies and vaccines to treat and prevent cancers and infectious diseases. The company is engaged in gene therapy, where its immunotherapy platform consists of DNA-based immunotherapy and electroporation delivery technologies.
Read more on INO →SGOL is an ETF that is designed to track the performance of the price of gold bullion. The fund is backed by physical gold held in secured vaults, which is allocated to the ETF's custodian account. By providing direct ownership of gold without the need for physical storage or insurance, SGOL offers investors a convenient and cost-effective way to gain exposure to the gold market.
Read more on SGOL →